CDK4 and breast cancer: Inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) in combination with hormonal therapy has been a highly effective treatment regimen for metastatic HR+ breast cancer with three FDA-approved agents – abemaciclib, palbociclib and ribociclib – showing similar outcomes with somewhat differing side effect profiles (44).